Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Generic Bottleneck Needs To Be Cleared "Now," Senators Tells FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Without suggesting a specific action, five Democratic senators urge a "timely action" from FDA on "previous filings."

You may also be interested in...



Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA

Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2

Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA

Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.

Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA

Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.

Related Content

Topics

UsernamePublicRestriction

Register

PS071936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel